Theradiag SA Asset Resilience Ratio
Theradiag SA asset resilience ratio. Theradiag SA (ALTHE) has an Asset Resilience Ratio of 15.59% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Theradiag SA fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Theradiag SA (2010–2023)
Asset resilience ratio of Theradiag SA from 2010 to 2023. This chart shows how Theradiag SA's Asset Resilience Ratio has changed over time. Read Theradiag SA total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Theradiag SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ALTHE asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.80 Million | 15.59% |
| Total Liquid Assets | €1.80 Million | 15.59% |
Asset Resilience Insights
- Good Liquidity Position: Theradiag SA maintains a healthy 15.59% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Theradiag SA Industry Peers by Asset Resilience Ratio
Compare Theradiag SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Shanghai Sanyou Medical Co Ltd
SHG:688085 |
Medical Devices | 7.69% |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607 |
Medical Devices | 16.21% |
|
Cleo Diagnostics Ltd
AU:COV |
Medical Devices | 94.64% |
|
Memphasys Ltd
AU:MEM |
Medical Devices | 0.00% |
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
Theradiag SA Asset Resilience Ratio by Year (2010–2023)
Theradiag SA asset resilience ratio by year from 2010 to 2023. The table below shows the annual Asset Resilience Ratio data for Theradiag SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -0.12% | €-21.82K ≈ $-25.51K |
€18.66 Million ≈ $21.82 Million |
-0.34pp |
| 2022-12-31 | 0.22% | €31.10K ≈ $36.36K |
€13.94 Million ≈ $16.30 Million |
-0.04pp |
| 2021-12-31 | 0.26% | €31.10K ≈ $36.36K |
€11.83 Million ≈ $13.83 Million |
-0.03pp |
| 2020-12-31 | 0.29% | €31.10K ≈ $36.36K |
€10.55 Million ≈ $12.33 Million |
0.00pp |
| 2019-12-31 | 0.30% | €31.10K ≈ $36.36K |
€10.51 Million ≈ $12.29 Million |
-0.03pp |
| 2018-12-31 | 0.33% | €31.10K ≈ $36.36K |
€9.56 Million ≈ $11.18 Million |
+0.10pp |
| 2017-12-31 | 0.23% | €31.10K ≈ $36.36K |
€13.77 Million ≈ $16.10 Million |
-33.97pp |
| 2016-12-31 | 34.19% | €5.03 Million ≈ $5.88 Million |
€14.71 Million ≈ $17.20 Million |
+14.41pp |
| 2015-12-31 | 19.78% | €1.83 Million ≈ $2.14 Million |
€9.26 Million ≈ $10.82 Million |
+1.29pp |
| 2014-12-31 | 18.50% | €1.53 Million ≈ $1.79 Million |
€8.28 Million ≈ $9.69 Million |
+17.44pp |
| 2013-12-31 | 1.06% | €31.10K ≈ $36.36K |
€2.94 Million ≈ $3.44 Million |
+0.08pp |
| 2012-12-31 | 0.97% | €31.10K ≈ $36.36K |
€3.20 Million ≈ $3.74 Million |
-23.96pp |
| 2011-12-31 | 24.93% | €575.16K ≈ $672.42K |
€2.31 Million ≈ $2.70 Million |
+24.66pp |
| 2010-12-31 | 0.27% | €10.60K ≈ $12.39K |
€3.91 Million ≈ $4.57 Million |
-- |
About Theradiag SA
Theraclion SA provides therapeutic ultrasound equipment. It offers SONOVEIN, a robotic solution for the non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for the echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment to protect the patient's skin and optimize imag… Read more